You are here

  • Home
  • Archive
  • Volume 19, Issue 6
  • Until questions on intraprocedural efficacy control, renal nerve distribution and predictors of BP response are answered, the interpretation of clinical trials on renal denervation will remain uncertain

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Until questions on intraprocedural efficacy control, renal nerve distribution and predictors of BP response are answered, the interpretation of clinical trials on renal denervation will remain uncertain

https://doi.org/10.1136/ebmed-2014-110028

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors LD, SE and MB have substantially contributed to the drafting of the commentary. All authors have approved the final version of the manuscript to be published.

    • Competing interests MB was the investigator of the Symplicity HTN-1 and HTN-2 trial. He has also received speaker honorarium and consultancy fees from Medtronic/Ardian, St. Jude, Boston Scientific, and Cordis. He is supported by Deutsche Forschungsgemeinschaft (KFO 196) and by Deutsche Gesellschaft für Kardiologie. SE is supported by Deutsche Hochdruckliga. The institution has received scientific support from Medtronic/Ardian.

    • Provenance and peer review Not commissioned; internally peer reviewed.